CD33 and acute myeloid leukemia: In R/R AML, venetoclax is being studied in combination with CDK9-inhibitors (NCT03441555), JAK2 inhibitor (NCT03874052), FLT3 inhibitors such as quizartinib (NCT03735875, NCT03661307) or gilteritinib (NCT04140487, NCT03625505), MCL1 inhibitor (NCT03672695), MEK/MDM2 inhibitor (NCT02670044), XPO1 inhibitor (NCT03955783) and anti-CD33 monoclonal antibodies (NCT03867682) [6].